Adicet Bio narrows Q3 net loss to $18.9 million from $26.9 million a year earlier
Adicet Bio reported a third-quarter 2026 net loss of $18.9 million, or $1.76 per share, compared with a net loss of $26.9 million, or $4.72 per share, in the same period of 2025. The company said its cash, cash equivalents and short-term investments of $100.9 million as of September 30, 2026, are expected to fund operating expenses into the second half of 2027.
Key points
- Net loss of $18.9 million, or $1.76 per share, for the quarter ended September 30, 2026, versus $26.9 million, or $4.72 per share, a year earlier
- R&D expenses fell to $15.6 million from $22.9 million, and G&A expenses fell to $4.2 million from $5.1 million
- Cash, cash equivalents and short-term investments were $100.9 million on September 30, 2026, down from $158.5 million on December 31, 2025
- Company expects current cash to fund operating expenses into the second half of 2027
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.